C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
SOHO State-of-the-Art Update and Next Questions: MPN.
TL;DR: The mechanisms through which mutant CALR drives JAK‐STAT pathway activation and oncogenic transformation are now better understood and an important milestone in mastocytosis research was reached in 2017 with the regulatory approval of midostaurin for patients with advanced systemic mastocyTosis (AdvSM).
Journal ArticleDOI
The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients
Holly L. Geyer,Amylou C. Dueck,Robyn M. Emanuel,Jean-Jacques Kiladjian,Stefanie Slot,Sonja Zweegman,Peter A. W. te Boekhorst,Suzan Commandeur,Harry C. Schouten,Federico Sackmann,Ana Kerguelen Fuentes,Dolores Hernández-Maraver,Heike L. Pahl,Martin Griesshammer,Frank Stegelmann,Konstanze Doehner,Françoise Boyer,Gabriel Etienne,Jean-Christophe Lanotto,Dana Ranta,Lydia Roy,Jean-Yves Cahn,Claire N. Harrison,Deepti Radia,Pablo J. Muxi,Norman Maldonado,Carlos Besses,Francisco Cervantes,Peter Johansson,Giovanni Barosi,Alessandro M. Vannucchi,Francesco Passamonti,Bjorn Andreasson,Maria L Ferarri,Alessandro Rambaldi,Jan Samuelsson,Gunnar Birgegård,Zhijian Xiao,Yue Zhang,Xiujuan Sun,Junqing Xu,Robert Peter Gale,Ayalew Tefferi,Peihong Zhang,Thomas Lehmann,Andreas Reiter,Karin Bonatz,Ruben A. Mesa +47 more
TL;DR: The Myelofibrosis Symptom Burden (MF-SB) : An International Phenotypic Cluster Analysis of 329 Patients shows clear trends in morbidity and mortality among patients diagnosed with MF.
Journal ArticleDOI
Treatment of Essential Thrombocythemia in Europe: An Observational Study of 3649 High-Risk Patients in Exels
Gunnar Birgegård,Carlos Besses,Martin Griesshammer,Luigi Gugliotta,Claire N. Harrison,Mohamed Hamdani,Heinrich Achenbach,Jean-Jacques Kiladjian +7 more
TL;DR: Treatment of Essential Thrombocythemia in Europe: An Observational Study of 3649 High-Risk Patients in Exels as mentioned in this paper, was conducted in Europe.
Journal ArticleDOI
MPN-038: Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study
Claire N. Harrison,Jacqueline S. Garcia,Ruben A. Mesa,Tim C. P. Somervaille,Ellen K. Ritchie,Rami S. Komrokji,Naveen Pemmaraju,Catriona Jamieson,Nikolaos Papadantonakis,James M. Foran,Casey O'Connell,Srdan Verstovsek,Paul M. Jung,Leanne Holes,Abdullah A. Masud,Jason Harb,Jessica E. Hutti,Josef T. Prchal +17 more
TL;DR: In this article, Navitoclax (Nav) and Ruxolitinib (Rux) were combined to overcome resistance to JAK2 inhibition, providing a disease modifying treatment for myelofibrosis (MF).
Journal ArticleDOI
Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study
Claire N. Harrison,Joanna Baxter,Rebecca H. Boucher,Thomas McKerrell,Thomas McKerrell,Aimee Jackson,Rachel Fletcher,Adam J. Mead,Steve Knapper,Joanne Ewing,Nauman M Butt,Manish Jain,Sebastian Francis,Fiona Clark,Jason Coppell,Mary Frances McMullin,Frances Wadelin,Srinivasan Narayanan,Dragana Milojkovic,Mark Drummond,Mallika Sekhar,Maike Paramor,James Roberts,Rachel Glover,Erica Harris,Luigi Grassi,Alba Rodriguez-Meira,Jason S. Carroll,Jose Ezequiel Martin,Giuditta Corbizi Fattori,Zijian Fang,Anna L. Godfrey,Anna L. Godfrey,Simón Méndez-Ferrer +33 more
TL;DR: A clinical trial assessing tamoxifen's safety and activity in reducing molecular markers of disease burden in MPN male patients aged ≥60 years and post-menopausal female patients with stable blood counts, no history of thrombosis and ≥20% mutated JAK2V617F, CALR 5bp insertion or CALR 52bp deletion.